Drug Discovery and Development Market in Asia - Partnerships Between MNCs and Asian Academic Institutions and Healthcare Research Organizations are Driving R&D Innovation

GBI Research
November 9, 2012
106 Pages - SKU: XGBR4910240
Countries covered: Asia



Drug Discovery and Development Market in Asia - Partnerships Between MNCs and Asian Academic Institutions and Healthcare Research Organizations are Driving R&D Innovation

Summary

GBI Research, a leading business intelligence provider, has released its latest research, “Drug Discovery and Development Market in Asia - Partnerships Between MNCs and Asian Academic Institutions and Healthcare Research Organizations are Driving R&D Innovation”. The report provides key data, information and analysis of the major trends and issues affecting the drug discovery and development market in seven major countries in Asia, namely China, India, Russia, Japan, Singapore, Taiwan and South Korea. The report provides a comprehensive insight into market segmentation, covering drug discovery and development market sizes, the strategic context for deciding a location in Asia to conduct clinical research, strategies adopted by global pharmaceutical companies in outsourcing R&D processes to Asian countries, and the regulatory landscapes there. The report provides a detailed analysis of the regulatory authorities, clinical trial approval processes and recent regulatory changes in the clinical trial environment. The report analyzes the competitive landscape of the market, profiling key Contract Research Organizations (CRO) market players, along with a brief description of the business, major services and major M&A and partnership deals. The report also provides detailed analysis of major partnership and M&A deals that have taken place in the Asian drug discovery and development market along with segmentation by year, deal type, geography and phase of development.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research finds that the total drug discovery and development market size in the top seven Asian countries was estimated at $5.3 billion in 2011 and is forecast to reach $17.3 billion by the end of 2018. Revenue growth has been surpassed by investments in pharmaceutical R&D that have not increased the output of new medicines. Research-based pharmaceutical companies outsource R&D processes to CROs which offer integrated services across the life-sciences R&D value chain. Globalization in the clinical trial industry has led to an increased number of trials being conducted in emerging markets.

The CRO industry has been witnessing strategic deals between large global CROs with broad therapeutic and functional expertise, and subcontracting local CROs. This will enable global CROs to increase their market access capabilities, thereby further increasing the extent of their outsourcing activities. The entry of new participants into the biopharmaceutical sector will augment the drug discovery and development market in Asian countries. For example, Samsung Electronics entered into the biopharmaceutical market in April 2011 through the formation of Samsung Biologics, a joint venture company between Samsung Electronics and Quintiles. In December, 2011 Samsung entered into another agreement with Biogen Idec to set up a joint venture for the development, manufacture and marketing of biosimilars.

Scope
  • Detailed overview of global trends in pharmaceutical R&D, followed by market segmentation of the Asian drug discovery and development market in seven major countries, which are China, India, Japan, South Korea, Taiwan, Russia and Singapore.
  • Annualized market data from 2007 and forecasts to 2018.
  • Strategies adopted by global pharmaceutical companies in outsourcing R&D processes to Asian countries, along with the strategic context for deciding locations in Asia for conducting clinical research.
  • Competitive landscape analysis, with profiles of the leading companies such as Quintiles Transnational Corp, Pharmaceutical Product Development Inc., Covance Inc., Parexel International Corporation and Charles River Laboratories International, Inc.
  • Analysis of partnership and M&A deals from 2004 to June 2012 along with segmentation by year and geography, deal type, and phases of development.
Reasons to buy
  • Align your product portfolio to markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the key areas for high growth and opportunities.
  • Understand the factors shaping the Asian drug discovery and development market.
  • Identify the key players best positioned to take the advantage of the opportunities in the Asian drug discovery and development market.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.


Additional Information

Drug Research in Asia Goes Native

High recruitment rates and a robust regulatory framework strongly favour the Asian clinical research industry - and now pharma giants are going beyond simple outsourcing to study the region’s own health problems, states a new report by healthcare experts GBI Research.

The new report* explains that Asia offers a favourable environment for pharmaceutical progress, thanks to low costs, a large potential trial population and regulatory support. For example, oncology studies have now started to investigate the Asian phenotype, in order to learn even more about the nature of cancer.

During this year, over 12% of global clinical trials were carried out in the seven major markets of Asia, trailing behind the US share of 48.5%, and Europe’s 26.5%. Many Western biopharmaceutical companies are beginning to take advantage of emerging countries, where Asian regulatory agencies are streamlining the clinical trial process to meet global demand for cheap clinical research, but the vast opportunity in Asia has not yet been fully leveraged by the developed markets.

The cost of conducting clinical trials in Asian countries is 35%–45% lower than the cost of conducting similar trials in the US, as they are able to recruit a large number of patients from urban centres easily and at a low cost. The regulatory systems in Asia also offer a favourable environment, as the adoption of Good Clinical Practice (GCP) guidelines and the establishment of Institutional Review Boards (IRBs) is helping the region to quickly evolve and integrate with international standards.

Oncology is a key therapeutic area where the study of Asian patients can help pharma companies. The regional population has a high prevalence of liver cancer (due to infections of hepatitis B and C), stomach cancer, and head and neck cancer, so companies are focusing on discovering and developing medicines specifically to treat Asian diseases. This has developed from an earlier trend of finding use of an approved drug developed for a non-Asian phenotype. The Asia Oncology Strategic Alliance, launched by AstraZeneca in 2007, highlights the interest pharmaceutical companies have in the discovery and development of medicines specifically to treat Asian diseases. The aim of the alliance was to evaluate novel treatments for stomach and liver cancers in China, Japan, South Korea and Singapore, as the governments of these countries prioritized cancer therapy.

GBI Research estimates that the total market size of China, India, Russia, Japan, Singapore, Taiwan and South Korea’s drug discovery and development markets reached an impressive $5.3 billion in 2011, following growth at a Compound Annual Growth Rate (CAGR) of 21.9% from 2007. The market is expected to reach $17.3 billion in 2018, at a CAGR of 18.4%.

*Drug Discovery and Development Market in Asia - Partnerships Between MNCs and Asian Academic Institutions and Healthcare Research Organizations are Driving R&D Innovation

This report provides key data, information and analysis of the major trends and issues affecting the drug discovery and development market in seven major countries in Asia, namely China, India, Russia, Japan, Singapore, Taiwan and South Korea. It provides a comprehensive insight into market segmentation, covering drug discovery and development market sizes, the strategic context for deciding a location in Asia to conduct clinical research, strategies adopted by global pharmaceutical companies in outsourcing R&D processes to Asian countries, and the regulatory landscapes there. The report also provides a detailed analysis of the regulatory authorities, clinical trial approval processes and recent regulatory changes in the clinical trial environment.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Companies Mentioned

Siemens Healthcare
Fresenius Medical Care AG & Co. KGaA
GE Healthcare
F. Hoffmann-La Roche Ltd.
Philips Healthcare
Essilor International
DePuy, Inc.
Medtronic, Inc.
Boston Scientific Corporation
Mindray Medical International Limited
Shandong Weigao Group Medical Polymer
WuHan VSD Medical Science & Technology Co. Ltd.
Neusoft Medical Systems Co., Ltd.

More Drug Discovery reports by GBI Research

Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options by GBI Research
Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment OptionsSummaryGBI Research, a leading business ...
Major Depressive Disorder Therapeutics in Major Developed Markets to 2020 - New Launches and Modest Uptake of New Adjunctive Treatments to Offset Patent Expiries by GBI Research
Major Depressive Disorder Therapeutics in Major Developed Markets to 2020 - New Launches and Modest Uptake of New Adjunctive Treatments to Offset Patent ExpiriesSummaryGBI Research, ...
Frontier Pharma: Non-Small Cell Lung Cancer - Identifying and Commercializing First-in-Class Innovation by GBI Research
Non-Small Cell Lung Cancer - Identifying and Commercializing First-in-Class InnovationSummaryLarge Degree of Innovation in NSCLC PipelineThe NSCLC pipeline currently has 389 products in active development ...
Acute Myeloid Leukemia Therapeutics Market to 2020 - Novel Therapies to Offer Clinical Benefit in Small Patient Cohorts by GBI Research
Acute Myeloid Leukemia Therapeutics Market to 2020 - Novel Therapies to Offer Clinical Benefit in Small Patient CohortsSummaryGBI Research, has released its latest pharma report, ...
See all reports like this >>

More Asia Drug Discovery reports

Central Nervous System Disorder Drugs Markets in China by Asia Market Information & Development Company
Central Nervous System Disorder Drugs Markets in ChinaChina's demand for Central Nervous System Disorder Drugs has grown at a fast pace in the past decade. ...
Lymphoma Treatment Drugs Markets in China by Asia Market Information & Development Company
Lymphoma Treatment Drugs Markets in ChinaChina's demand for Lymphoma Treatment Drugs has grown at a fast pace in the past decade. In the next decade, ...
Anti-Tumor Drugs Markets in China by Asia Market Information & Development Company
Anti-Tumor Drugs Markets in ChinaChina's demand for Anti-Tumor Drugs has grown at a fast pace in the past decade. In the next decade, both production ...
Osteoporosis Drugs Markets in China by Asia Market Information & Development Company
Osteoporosis Drugs Markets in ChinaChina's demand for Osteoporosis Drugs has grown at a fast pace in the past decade. In the next decade, both production ...
See all reports like this >>

More Asia reports

Asia: Industrial Roundwood – Market Report. Analysis and Forecast to 2020 by IndexBox Marketing Ltd.
Asia: Industrial Roundwood – Market Report. Analysis and Forecast to 2020 The report provides an in-depth analysis of the Asian Market of Industrial Roundwood. It ...
Spirits - BRIC (Brazil, Russia, India, China) Industry Guide by MarketLine
IntroductionThe BRIC Spirits industry guide provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2009-13, and forecast to 2018). ...
BC - West Sulawesi Cocoa Processing Plant - Indonesia - Construction Project Profile by World Market Intelligence
BC - West Sulawesi Cocoa Processing Plant - Indonesia - Construction Project Profile-SynopsisThe BC - West Sulawesi Cocoa Processing Plant - Indonesia - Construction Project ...
D&B Country Report: Sri Lanka by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 3,500  
    Site License  USD 7,000  
    Global Site License  USD 10,500  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!